Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist
- PMID: 12438928
- DOI: 10.1097/00001756-200211150-00016
Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist
Abstract
The aim of this study was to evaluate the neuroprotective effect of CHF3381, a novel putative NMDA antagonist characterized by a good therapeutic index. We have compared the effects of CHF3381 on kainate seizure-induced neurodegeneration with those produced by the non competitive NMDA receptor antagonist MK-801 and by the Na channel blocker lamotrigine. All compounds have been employed at doses incapable of preventing or attenuating seizures. The fluorescent marker Fluoro-Jade B has been used to identify degenerating cells. Animals pretreated with lamotrigine presented the same degree of cell damage as the controls. As for the controls, a clear correlation was also observed between seizure severity and neurodegeneration. In contrast, MK-801 and CHF3381 completely prevented cell damage. These data indicate that CHF3381 may be successfully utilized in neurological disorders characterized by or associated with neurodegenerative excitotoxicity.
Similar articles
-
Mechanisms of action of CHF3381 in the forebrain.Br J Pharmacol. 2003 Aug;139(7):1333-41. doi: 10.1038/sj.bjp.0705381. Br J Pharmacol. 2003. PMID: 12890713 Free PMC article.
-
Preclinical evaluation of CHF3381 as a novel antiepileptic agent.Neuropharmacology. 2001 Jun;40(7):866-78. doi: 10.1016/s0028-3908(01)00026-0. Neuropharmacology. 2001. PMID: 11378157
-
A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity.J Pharmacol Exp Ther. 2002 Jul;302(1):163-73. doi: 10.1124/jpet.302.1.163. J Pharmacol Exp Ther. 2002. PMID: 12065713
-
N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy.Neuroscience. 2003;118(3):727-40. doi: 10.1016/s0306-4522(03)00027-7. Neuroscience. 2003. PMID: 12710980
-
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.J Pain. 2006 Aug;7(8):565-74. doi: 10.1016/j.jpain.2006.02.004. J Pain. 2006. PMID: 16885013 Clinical Trial.
Cited by
-
Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.Br J Clin Pharmacol. 2005 Apr;59(4):405-14. doi: 10.1111/j.1365-2125.2005.02338.x. Br J Clin Pharmacol. 2005. PMID: 15801935 Free PMC article. Clinical Trial.
-
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model.Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7191-6. doi: 10.1073/pnas.0810710106. Epub 2009 Apr 6. Proc Natl Acad Sci U S A. 2009. PMID: 19366663 Free PMC article.
-
From fix to fit into the autoptic human brains.Eur J Histochem. 2018 Aug 27;62(3):2944. doi: 10.4081/ejh.2018.2944. Eur J Histochem. 2018. PMID: 30173504 Free PMC article.
-
Mechanisms of action of CHF3381 in the forebrain.Br J Pharmacol. 2003 Aug;139(7):1333-41. doi: 10.1038/sj.bjp.0705381. Br J Pharmacol. 2003. PMID: 12890713 Free PMC article.
-
Fgf-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss.J Neurosci. 2008 Dec 3;28(49):13112-24. doi: 10.1523/JNEUROSCI.1472-08.2008. J Neurosci. 2008. PMID: 19052202 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials